Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.38 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.38 |
| ▸ | GALR3 | O60755 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1065760 | 0.83 | ALDH1A1 (0.52) | ALDH1A1TSHRCHRM5CHRM1CHRM3 | |
| SCHEMBL1270603 | 0.79 | ALDH1A1 (0.48) | ALDH1A1TSHRCHRM5CHRM1CHRM3 | |
| SCHEMBL21567171 | 0.78 | ALDH1A1 (0.39) | ALDH1A1TSHRCHRM5CHRM1CHRM3 | |
| SCHEMBL23394670 | 0.78 | ALDH1A1 (0.47) | ALDH1A1TSHRCHRM5CHRM1CHRM3 | |
| SCHEMBL24778731 | 0.78 | ALDH1A1 (0.47) | ALDH1A1TSHRCHRM5CHRM1CHRM3 | |
| SCHEMBL13120306 | 0.77 | ALDH1A1 (0.46) | ALDH1A1TSHRCHRM5CHRM1CHRM3 | |
| SCHEMBL16247768 | 0.75 | ALDH1A1 (0.45) | ALDH1A1TSHRCHRM5CHRM1CHRM3 | |
| SCHEMBL464483 | 0.75 | ALDH1A1 (0.56) | ALDH1A1TSHRCHRM5CHRM1CHRM3 | |
| SCHEMBL64593 | 0.72 | ALDH1A1 (0.68) | ALDH1A1TSHRCHRM5CHRM1CHRM3 | |
| SCHEMBL330791 | 0.72 | ALDH1A1 (0.50) | ALDH1A1TSHRCHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9914924-B2 | Methods and compositions for treating neurological disease | UNIVERSITY OF MASSACHUSETTS (US) | 2018-03-13 | — | — | US | disclosed |
| US-8354524-B2 | Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120065387-A1 | SYNTHESIS OF SELENIUM-DERIVATIZED NUCLEOSIDES, NUCLEOTIDES, PHOSPHORAMIDITES, TRIPHOSPHATES AND NUCLEIC ACIDS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-7982030-B2 | Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110166198-A1 | RNA COMPOSITIONS FOR MODULATING IMMUNE RESPONSE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20100267941-A1 | IRNA AGENTS WITH BIOCLEAVABLE TETHERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267810-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | UNIVERSITY OF MASSACHUSETTS (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100137573-A1 | SYNTHESIS OF SELENIUM-DERIVATIZED NUCLEOSIDES, NUCLEOTIDES, PHOSPHORAMIDITES, TRIPHOSPHATES AND NUCLEIC ACIDS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7592446-B2 | Useful in structural determinations, particularly by X-ray crystallographic techniques; useful as food supplements | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592446-B2 | Useful in structural determinations, particularly by X-ray crystallographic techniques; useful as food supplements | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-7582744-B2 | containing 2'-O-methyl modified nucleoside; oligonucleotide having a nucleotide sequence consisting of from 12 to 23 nucleotides in length sufficiently complementary to a microRNA target sequence of about 12 to 23 nucleotides, conjugate with a cholesterol or steroid; for inhibiting gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070105803-A1 | Methods and compositions for treating neurological disease | MASSACHUSETTS, UNIVERSITY OF | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137573-A1 | SYNTHESIS OF SELENIUM-DERIVATIZED NUCLEOSIDES, NUCLEOTIDES, PHOSPHORAMIDITES, TRIPHOSPHATES AND NUCLEIC ACIDS | SELENOI, RNGTT, NT5C3B | ALDH1A1 3517/4885TSHR 1614/4885CHRM5 4234/4885 |
| US-20110166198-A1 | RNA COMPOSITIONS FOR MODULATING IMMUNE RESPONSE | EIF2AK2, IRF3, NSUN2 | ALDH1A1 4606/4885TSHR 2429/4885CHRM5 4267/4885 |
| US-20100267810-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | SMN1; SMN2, CLN6, INA | ALDH1A1 2103/4885TSHR 4453/4885CHRM5 4272/4885 |
| US-20070105803-A1 | Methods and compositions for treating neurological disease | SMN1; SMN2, CLN6, INA | ALDH1A1 2103/4885TSHR 4453/4885CHRM5 4272/4885 |
| US-20100267941-A1 | IRNA AGENTS WITH BIOCLEAVABLE TETHERS | DCLRE1A, PARP1, LIG1 | ALDH1A1 1003/4885TSHR 3048/4885CHRM5 4816/4885 |
| US-20120065387-A1 | SYNTHESIS OF SELENIUM-DERIVATIZED NUCLEOSIDES, NUCLEOTIDES, PHOSPHORAMIDITES, TRIPHOSPHATES AND NUCLEIC ACIDS | SELENOI, RNGTT, NT5C3B | ALDH1A1 3517/4885TSHR 1614/4885CHRM5 4234/4885 |
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | ALDH1A1 1923/4885TSHR 4147/4885CHRM5 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.